Evidence map›Paper›PMID 34430363›Full record

ReviewTranslational lung cancer research2021

A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future.

Sijia Ren, Anyi Xu, Yilian Lin, D Ross Camidge, Massimo Di Maio, Raffaele Califano, Toyoaki Hida, Antonio Rossi, Nicolas Guibert, Chengchu Zhu and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Neoadjuvant Osimertinib for ResectableJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Trial
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Current neoadjuvant therapy for operable locally advanced esophageal cancer.Medical oncology (Northwood, London, England) · 2023
    Review
  8. Neoadjuvant Immunotherapy: A Promising New Standard of Care.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sijia RenTaizhou Hospital, Zhejiang University, Taizhou, China.
Anyi XuTaizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, China.
Yilian LinTaizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Taizhou, China.
D Ross CamidgeDivision of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Massimo Di MaioDepartment of Oncology, University of Turin/Division of Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy.
Raffaele CalifanoDepartment of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.
Toyoaki HidaDepartment of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi, Japan.
Antonio RossiOncology Center of Excellence, Therapeutic Science & Strategy Unit, IQVIA, Milan, Italy.
Nicolas GuibertThoracic Oncology Department, Larrey Hospital, University Hospital of Toulouse, Toulouse, France.
Chengchu ZhuTaizhou Hospital, Zhejiang University, Taizhou, China.
Jianfei ShenTaizhou Hospital, Zhejiang University, Taizhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis review summarizes the current status of neoadjuvant therapy and discusses the choice of new clinical research endpoints for non-small cell lung cancer.

backgroundNeoadjuvant chemotherapy is a recognized practice in patients with resectable and locally advanced lung cancer. With the introduction of molecular targeted drugs and immune checkpoint inhibitors (ICIs), the overall survival (OS) of patients with lung cancer has been significantly improved, and the original traditional clinical research endpoints are no longer suitable for existing clinical research. In order to accelerate the process of clinical trials and the development and approval of drugs, it is necessary to find suitable alternative indicators as the main indicators of clinical research.

methodsTherefore, this article focuses on clinical trials using disease-free survival (DFS), progression free survival, and pathological evaluation indicators, pathologic complete response and major pathologic response, as surrogate endpoints. We search related literature through PubMed database and clinical trials through clinicaltrials.gov.

conclusionsPathologic complete response and major pathologic response are recommended as surrogate endpoints in the era of neoadjuvant immunotherapy, and secondary endpoints are listed for the prediction of pathological results. In addition, the definitions of major pathological response (MPR) and PCR should be standardized, and a new pathological evaluation standard should be developed, which is applicable to all current treatment methods. KEYWORDS: Neoadjuvant therapy; resectable lung cancer; clinical research endpoint; pathological response.

Identifiers

PMID34430363
PMCPMC8350086

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.